Ultragenyx Pharmaceutical (RARE) Other Accumulated Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Other Accumulated Expenses data on file, last reported at $17.0 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 407.77% year-over-year to $17.0 million in Q1 2026; TTM through Mar 2026 was $17.0 million, a 407.77% increase from a year earlier, with the FY2025 full-year figure at $19.0 million, up 375.0% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $17.0 million, down from $19.0 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for RARE reached as high as $59.9 million in Q3 2022 and fell as low as $1.2 million in Q3 2025.
• Historically, Other Accumulated Expenses has averaged $30.7 million across 5 years, with a median of $31.2 million in 2023.
• Across the five-year window, Other Accumulated Expenses plunged 93.33% in 2025 and jumped 407.77% in 2026, its largest moves.
• Year by year, Other Accumulated Expenses stood at $52.2 million in 2022, then slumped by 40.22% to $31.2 million in 2023, then sank by 87.18% to $4.0 million in 2024, then jumped by 375.0% to $19.0 million in 2025, then declined by 10.53% to $17.0 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $17.0 million in Q1 2026, $19.0 million in Q4 2025, and $1.2 million in Q3 2025.